Genetically modified «hunter» T cells successfully migrated to and penetrated a
deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be
overcome to better treat this aggressive
cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.